Perfuze wins FDA clearance for standalone aspiration catheter

Perfuze announced today that it received FDA 510(k) clearance for its Millipede88 aspiration catheter.

Galway, Ireland-based Perfuze designed the catheter for rapid and complete clot removal in patients suffering from large vessel occlusion (LVO) strokes. The company aims to improve stroke treatment outcomes and reduce procedural complexity.

Millipede88 features a patented corrugated catheter architecture designed to simplify navigation through the neurovascular anatomy. Its design helps to preserve inner lumen integrity to maintain maximum aspiration force at the face of the clot. Perfuze said it achieves high first-pass reperfusion rates and short procedure times in mechanical thrombectomy.

Sign up for Blog Updates